Abstract: Salubris, a CKM-focused innovative pharmaceutical company, is seeking an A+H listing. Goldman Sachs, Citi, and CITIC are the sponsors. We look at the company's core segments: innovative drugs and other pharmaceuticals. We discussed our preliminary thoughts on the company's valuation based on A-H premium.
LIVZON PHARMACEUTICAL, CHINA RESOURCES SANJIU MEDICAL & PHARMACEUTICAL, HUALAN BIOLOGICAL ENGINEERING, SHENZHEN SALUBRIS PHARMACEUTICALS, CSPC Pharma, HENGRUI PHARMA, LIVZON PHARMA, FOSUN PHARMA, Fosun Pharma, JIANGSU HENGRUI MEDICINE, TASLY PHARMACEUTICA
Interested in the full report? Get in touch with our team.